Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II clarithromycin + lenalidomide in MALT lymphoma
2015-003168-35Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clarithromycin and lenalidomide in extranodal marginal zone B-cell lymphoma (EMZL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoint: Overall tumor response rate. Started Aug 2016; status: completed.
02
Drugs
clarithromycinlenalidomide
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on 2015-003168-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003168-35.